Michael J. DiMartino
Michael J. DiMartino publishes mostly in Organic Chemistry, Immunology and Oncology, on topics such as Metal complexes synthesis and properties, Inflammatory mediators and NSAID effects and Organometallic Compounds Synthesis and Characterization.
- World rank
- #1,347,467 of 7,710,434 ranked researchers
- Rank in United States
- #427,166 of 1,627,098
- Works
- 71
- Citations
- 2k
- Citations per work
- 28.8
What does Michael J. DiMartino research?
Michael J. DiMartino's work is mostly in Chemistry (22%), Medicine (19%), Immunology and Microbiology (10%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Everything else2941.1%
- Physical Sciences1622.4%
- Chemistry1622.4%
- Health Sciences1419.3%
- Medicine1419.3%
- Life Sciences1217.2%
- 1Organic Chemistry22% of their works
- 2Immunology10% of their works
- 3Oncology9% of their works
- 4Molecular Biology7% of their works
- 5Rheumatology5% of their works
- 6Pharmacology5% of their works
Research topics
- Metal complexes synthesis and properties
- Inflammatory mediators and NSAID effects
- Organometallic Compounds Synthesis and Characterization
- Rheumatoid Arthritis Research and Therapies
- Pharmacological Effects of Natural Compounds
- Synthesis and biological activity
- Synthesis and Reactions of Organic Compounds
- Synthesis and Biological Evaluation
Which keywords describe Michael J. DiMartino's research?
The keywords of their largest research topics: Anticancer Agents, Inflammation, Metal Complexes, Synthesis, Cardiovascular Risk, Cancer, Cisplatin Resistance and Platinum-Based Drugs.
- Tubulin Inhibitors
- Oxazolones
- Imidazoles
- Antimicrobial Activity
- Organotin Compounds
- Biological Therapy
- Cyclooxygenase-2 Inhibitors
- Heterocyclic Compounds
- Platinum-Based Drugs
- Cancer
- Synthesis
- Inflammation
- Anticancer Agents
- Metal Complexes
- Cardiovascular Risk
- Cisplatin Resistance
- Catalyst
- Medicinal Chemistry
- Prostaglandins
- Chemistry
- Rheumatoid Arthritis
- Glycyrrhizin
- Licorice
- Quinoxaline
- Vascular Targeting Agents
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 25 words, with their numbers
- Anticancer Agents213 topics
- Inflammation203 topics
- Metal Complexes182 topics
- Synthesis173 topics
- Cardiovascular Risk152 topics
- Cancer132 topics
- Cisplatin Resistance111 topic
- Platinum-Based Drugs111 topic
- Catalyst102 topics
- Heterocyclic Compounds102 topics
- Medicinal Chemistry102 topics
- Cyclooxygenase-2 Inhibitors81 topic
- Prostaglandins81 topic
- Biological Therapy71 topic
- Chemistry71 topic
- Organotin Compounds71 topic
- Rheumatoid Arthritis71 topic
- Antimicrobial Activity51 topic
- Glycyrrhizin51 topic
- Imidazoles51 topic
- Licorice51 topic
- Oxazolones51 topic
- Quinoxaline51 topic
- Tubulin Inhibitors51 topic
- Vascular Targeting Agents51 topic
Where does Michael J. DiMartino work?
Michael J. DiMartino's main affiliation in the publication record is New Frontier, United States.
How many publications and citations does Michael J. DiMartino have?
OpenAlex counts 71 works and 2,047 citations for Michael J. DiMartino, an h-index of 26, ranking #1,347,467 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Michael J. DiMartino. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.